The Second Coming: Tysabri Ready For Blockbuster Status?
This article was originally published in RPM Report
Executive Summary
Tysabri was a sure-fire blockbuster before its withdrawal. Expectations are still high now that it's been given a second chance.
You may also be interested in...
FDA/IoM “Uncertainty” Conference Adds Uncertainty to Biogen Growth Plans For Tysabri
An FDA/Institute of Medicine workshop on characterizing and communicating the uncertainty inherent in risk/benefit decisions touched on an important topic for every sponsor. But two “case studies” included points a very particular interest to Biogen Idec, and to sponsors in the COPD class.
The Prasugrel Backlash: Another Black Eye for FDA's Advisory Committee Process
FDA is the first to acknowledge that a lot of things went wrong during the run-up to the prasugrel advisory committee meeting, not the least of which is how the agency handles allegations of intellectual bias among its members. For drug sponsors, it may mean that the rules of engagement have changed.
The Prasugrel Backlash: Another Black Eye for FDA's Advisory Committee Process
FDA is the first to acknowledge that a lot of things went wrong during the run-up to the prasugrel advisory committee meeting, not the least of which is how the agency handles allegations of intellectual bias among its members. For drug sponsors, it may mean that the rules of engagement have changed.